Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Key Considerations in Choosing Quadruplet vs. Triplet Therapy for Transplant-Preferred NDMM
OPTec: Outpatient Teclistamab Step-Up Administration and Its Real-World Practice Implications
Patient Case: 68-Year-Old Woman with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Dr. Sborov Discusses Long-Term Effects of CAR T-Cell Therapy in Myeloma.
Unmet Needs and Future Prospects for GPRC5D Bispecific Therapy
Potential Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment
Patient Case: 67-Year-Old BCMA-Naïve Woman with Relapsed/Refractory Multiple Myeloma
Enhancing Patient Reintegration into Community Care After Bispecifics Treatment in Myeloma.
Improving Communication Between Academic and Community Oncologists in Myeloma Treatment.
Sequencing Bispecifics and CAR T-Cell Therapies in Relapsed Refractory Multiple Myeloma
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Key Considerations in Choosing Quadruplet vs. Triplet Therapy for Transplant-Preferred NDMM
OPTec: Outpatient Teclistamab Step-Up Administration and Its Real-World Practice Implications
Patient Case: 68-Year-Old Woman with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Dr. Sborov Discusses Long-Term Effects of CAR T-Cell Therapy in Myeloma.
Unmet Needs and Future Prospects for GPRC5D Bispecific Therapy
Potential Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment
Patient Case: 67-Year-Old BCMA-Naïve Woman with Relapsed/Refractory Multiple Myeloma
Enhancing Patient Reintegration into Community Care After Bispecifics Treatment in Myeloma.
Improving Communication Between Academic and Community Oncologists in Myeloma Treatment.
Sequencing Bispecifics and CAR T-Cell Therapies in Relapsed Refractory Multiple Myeloma
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
